Rezolute Past Earnings Performance

Past criteria checks 0/6

Rezolute's earnings have been declining at an average annual rate of -24.2%, while the Biotechs industry saw earnings growing at 22.1% annually.

Key information

-24.2%

Earnings growth rate

45.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-61.1%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

May 22
We Think Rezolute (NASDAQ:RZLT) Needs To Drive Business Growth Carefully

Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Feb 13
Rezolute, Inc. (NASDAQ:RZLT) Shares Could Be 31% Above Their Intrinsic Value Estimate

Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Sep 21
Rezolute, Inc.'s (NASDAQ:RZLT) Intrinsic Value Is Potentially 65% Above Its Share Price

Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

Jul 25
Here's Why We're Watching Rezolute's (NASDAQ:RZLT) Cash Burn Situation

We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Jan 31
We Think Rezolute (NASDAQ:RZLT) Can Afford To Drive Business Growth

Rezolute GAAP EPS of -$0.37

Sep 15

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

May 06
We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

Rezolute shares rise on positive topline results from RZ402 eye disease trial

May 04

What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Jan 12
What Type Of Shareholders Make Up Rezolute, Inc.'s (NASDAQ:RZLT) Share Registry?

Revenue & Expenses Breakdown

How Rezolute makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:RZLT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-691656
30 Jun 240-681555
31 Mar 240-581447
31 Dec 230-571449
30 Sep 230-561448
30 Jun 230-521343
31 Mar 230-481241
31 Dec 220-441136
30 Sep 220-431034
30 Jun 220-411032
31 Mar 220-38928
31 Dec 210-31923
30 Sep 210-25918
30 Jun 210-21815
31 Mar 210-18713
31 Dec 200-19613
30 Sep 200-19514
30 Jun 200-20614
31 Mar 200-20614
31 Dec 190-37725
30 Sep 190-34721
30 Jun 190-33719
31 Mar 190-42724
31 Dec 180-25812
30 Sep 180-27814
30 Jun 180-30917
31 Mar 180-241013
31 Dec 170-27914
30 Sep 170-27914
30 Jun 170-24812
31 Mar 170-27612
31 Dec 160-22511
30 Sep 160-21510
30 Jun 160-2159
31 Mar 160-1459
31 Dec 150-1458
30 Sep 150-1257
30 Jun 150-1165
31 Mar 150-1063
31 Dec 140-1272
30 Sep 140-1160
30 Jun 140-1050
31 Mar 140-940

Quality Earnings: RZLT is currently unprofitable.

Growing Profit Margin: RZLT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RZLT is unprofitable, and losses have increased over the past 5 years at a rate of 24.2% per year.

Accelerating Growth: Unable to compare RZLT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RZLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: RZLT has a negative Return on Equity (-61.1%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies